Physician profile
Mehul H Nagarsheth
NPI 1073774774
$31,728.08
in general payments reported to CMS, 2019-2025
25 companies · $11K in 2025
The $11K reported for 2025 was more than what 92% of Glaucoma Specialist providers received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $356 · 2020: $885 · 2021: $1,030 · 2022: $2,741 · 2023: $2,744 · 2024: $13K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Food and Beverage: $7,559 · Travel and Lodging: $1,821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,336.02 |
| Food and Beverage | $7,558.94 |
| Travel and Lodging | $1,820.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $19,822.06 | 2019-2025 | Idose, Travoprost Intraocular Implant - Idose, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Abbvie INC. | $3,005.72 | 2022-2025 | |
| Sight Sciences, INC. | $1,917.45 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument |
| Alcon Vision LLC | $1,503.13 | 2019-2025 | Hydrus Microstent, Clareon, Rocklatan |
| New World Medical,INC. | $1,348.62 | 2021-2025 | Clearpath, Streamline, Kahook Dual Blade |
| Allergan, INC. | $1,154.67 | 2019-2022 | |
| Nova Eye, INC. | $1,019.84 | 2023-2025 | |
| Tarsus Pharmaceuticals, INC. | $351.53 | 2024-2025 | Xdemvy |
| Iridex Corporation | $286.37 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $253.95 | 2022-2023 | Vyzulta |
| Ivantis, INC | $246.08 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $189.62 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $167.35 | 2020-2025 | Catalys System, Tecnis Iol, Veritas Vision System |
| Novartis Pharmaceuticals Corporation | $69.38 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $63.51 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $60.88 | 2024-2025 | Eylea Hd |
| Kala Pharmaceuticals, INC. | $51.00 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $48.18 | 2019-2021 | |
| Rxsight INC | $37.48 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Amgen INC. | $35.02 | 2025 | Tepezza |
| Thea Pharma INC. | $34.29 | 2022-2023 | Iyuzeh |
| Akorn Operating Company LLC | $22.45 | 2021 | |
| Alcon Research LLC | $14.38 | 2019 | |
| Shire North American Group INC | $12.89 | 2019 | |
| Ocular Therapeutix, INC. | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mehul Nagarsheth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.